salvage therapy by amidotrizoate for sudden deafness showing poor response to steroid therapy

salvage therapy by amidotrizoate for sudden deafness showing poor response to steroid therapy - salvage therapy by amidotrizoate for sudden deafness showing poor response to steroid therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028794

Enrollment

100

Registered

2017-09-01

Start date

2017-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden deafness showing poor response to initial treatment with topical or systemic administration of steroid

Interventions

twenty milliliter of amidotrizoate is slowly administered intravenously once a day during 7 continuous days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: sudden deafness showing poor response to initial treatment with topical or systemic administration of steroid

Exclusion criteria

Exclusion criteria: 1. old case 2. thyroid disease 3. allergic disorder including bronchial asthma 4. renal dysfunction 5. past history of cerebellovascular disease and/or brain tumor

Design outcomes

Primary

Measure	Time frame
adverse effect during amidotrizoate therapy	—

Secondary

Measure	Time frame
hearing level measured by pure tone audiometry at the end of amidotrizoate therapy	—

Countries

Japan

Contacts

Public ContactTakahiro Nakashima

University of Miyazaki Department of otorhinolaryngology, head and neck surgery

takahiro_nakashima@med.miyazaki-u.ac.jp+85-985-85-2966

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026